Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab

Journal of Neuroimmunology

Volumn 261, Issue 1-2, 2013, Pages 123-128

  Lin, Jerry ^a   Bettin, Peggy ^a   Lee, John K ^a   Ho, Joseph K ^a   Sadiq, Saud A ^a  

^a Multiple Sclerosis Research Center of New York Inc   (United States)

Author keywords

Cerebrospinal fluid; JCV; Multiple sclerosis; Natalizumab; PML; Tysabri

Indexed keywords

JC VIRUS ANTIBODY; NATALIZUMAB; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS DNA;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SEROCONVERSION; VIRUS REACTIVATION;

CEREBROSPINAL FLUID; JCV; MULTIPLE SCLEROSIS; NATALIZUMAB; PML; TYSABRI;

ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; BIOLOGICAL MARKERS; HUMANS; JC VIRUS; LONGITUDINAL STUDIES; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84880778835     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.05.009     Document Type: Article

References (15)

1. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., Lee S., Plavina T., Scanlon J.V., Sandrock A., Bozic C. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2012, 366:1870-1880.
2. Cinque P., Cleator G.M., Weber T., Monteyne P., Sindic C.J., van Loon A.M. The role of laboratory investigation in the diagnosis and management of patients with suspected herpes simplex encephalitis: a consensus report. The EU Concerted Action on Virus Meningitis and Encephalitis. J. Neurol. Neurosurg. Psychiatry 1996, 61:339-345.
3. Clifford D.B., De Luca A., Simpson D.M., Arendt G., Giovannoni G., Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol. 2010, 9:438-446.
4. Delbue S., Branchetti E., Boldorini R., Vago L., Zerbi P., Veggiani C., Tremolada S., Ferrante P. Presence and expression of JCV early gene large T Antigen in the brains of immunocompromised and immunocompetent individuals. J. Med. Virol. 2008, 80:2147-2152.
5. Gorelik L., Lerner M., Bixler S., Crossman M., Schlain B., Simon K., Pace A., Cheung A., Chen L.L., Berman M., Zein F., Wilson E., Yednock T., Sandrock A., Goelz S.E., Subramanyam M. Anti-JC virus antibodies: implications for PML risk stratification. Ann. Neurol. 2010, 68:295-303.
6. Jacobi C., Lange P., Reiber H. Quantitation of intrathecal antibodies in cerebrospinal fluid of subacute sclerosing panencephalitis, herpes simplex encephalitis and multiple sclerosis: discrimination between microorganism-driven and polyspecific immune response. J. Neuroimmunol. 2007, 187:139-146.
7. Laroni A., Giacomazzi C.G., Grimaldi L., Gallo P., Sormani M.P., Bertolotto A., McDermott J.L., Gandoglia I., Martini I., Vitello G., Rinaldi F., Barzon L., Militello V., Pizzorno M., Bandini F., Capello E., Palu G., Uccelli A., Mancardi G.L., Varnier O.E. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J. Neuroimmune Pharmacol. 2007, 7:665-672.
8. Pohl D., Rostasy K., Jacobi C., Lange P., Nau R., Krone B., Hanefeld F. Intrathecal antibody production against Epstein-Barr and other neurotropic viruses in pediatric and adult onset multiple sclerosis. J. Neurol. 2010, 257:212-216.
9. Polman C.H., O'Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., Toal M., Lynn F., Panzara M.A., Sandrock A.W. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 354:899-910.
10. Rudick R.A., O'Connor P.W., Polman C.H., Goodman A.D., Ray S.S., Griffith N.M., Jurgensen S.A., Gorelik L., Forrestal F., Sandrock A.W., S, E.G. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann. Neurol. 2010, 68:304-310.
11. Sadiq S.A., Ladoulis C., McKendall R.R. The humoral immune response to virus infection. Handbook of Clinical Neurology 1989, 56:51-64. Elsevier Science, Amsterdam. P.J. Vinken, G.W. Bruyn, H.L. Klawans (Eds.).
12. Tavazzi E., Ferrante P., Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin. Microbiol. Infect. 2011, 17:1776-1780.
13. Tornatore C., Berger J.R., Houff S.A., Curfman B., Meyers K., Winfield D., Major E.O. Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy. Ann. Neurol. 1992, 31:454-462.
14. Trampe A.K., Hemmelmann C., Stroet A., Haghikia A., Hellwig K., Wiendl H., Goelz S., Ziegler A., Gold R., Chan A. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort. Neurology 2012, 78:1736-1742.
15. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., Barkhof F., Radue E.W., Jager H.R., Clifford D.B. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2006, 354:924-933.